FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Aging-related diseases, especially cancer, necessitate innovative therapeutic approaches.
• Chimeric antigen receptor (CAR) T cell therapy is a significant advancement in immuno-oncology, engineering T cells to target tumor antigens.
• Identifying novel, cancer-specific targets is crucial for enhancing CAR T cell therapy efficacy.

Purpose of the Study:

• To identify novel membrane-associated proteins on cancer cells for potential therapeutic targeting.
• To evaluate FAM168B and FAM168A as candidate targets for CAR T cell therapy development.
• To explore the potential of FAM168B as a tumor-specific antigen for novel cancer immunotherapies.

Main Methods:

• Bioinformatic analysis and literature review to identify candidate proteins.
• Characterization of FAM168B and FAM168A expression patterns in cancer cells.
• Assessment of FAM168B's potential as a target for CAR T cell recognition.

Main Results:

• FAM168B (family with sequence similarity 168 member B) and FAM168A were identified as candidate membrane-associated proteins expressed on cancer cell surfaces.
• FAM168B exhibits unique characteristics suggesting its suitability as a tumor-specific target.
• FAM168A (tongue cancer resistance-associated protein 1) was also identified as a related protein.

Conclusions:

• FAM168B represents a promising novel target for the development of CAR T cell therapies.
• Targeting FAM168B could broaden the application of CAR T cell therapy to a wider range of cancer types.
• This research supports the design of more precise and versatile cancer treatment strategies.